Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
26.8M
-
Number of holders
-
25
-
Total 13F shares, excl. options
-
5.27M
-
Shares change
-
+86.7K
-
Total reported value, excl. options
-
$13.8M
-
Value change
-
-$20.2K
-
Put/Call ratio
-
0
-
Number of buys
-
8
-
Number of sells
-
-11
-
Price
-
$2.62
Significant Holders of Eton Pharmaceuticals, Inc. - Common Stock (ETON) as of Q2 2022
31 filings reported holding ETON - Eton Pharmaceuticals, Inc. - Common Stock as of Q2 2022.
Eton Pharmaceuticals, Inc. - Common Stock (ETON) has 25 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.27M shares
of 26.8M outstanding shares and own 19.64% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (2.46M shares), VANGUARD GROUP INC (873K shares), AWM Investment Company, Inc. (463K shares), Roumell Asset Management, LLC (449K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (266K shares), PARADIGM CAPITAL MANAGEMENT INC/NY (200K shares), GEODE CAPITAL MANAGEMENT, LLC (187K shares), Bank of New York Mellon Corp (78.9K shares), STATE STREET CORP (77.9K shares), and BLAIR WILLIAM & CO/IL (38.9K shares).
This table shows the top 25 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.